Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks
Aquestive Therapeutics (AQST) reported Q3 2026 revenue of $7.6M, down from $12.8M in Q3 2025, with a net loss of $16.5M. The company resubmitted its Anifilm NDA, with an FDA action date of March 16, 2027, and received a $10M upfront payment for out-licensing Libervant. AQST expects to end 2026 with over $70M in cash and is preparing for Anifilm's U.S. launch, hiring 75 sales reps. The FDA review timeline and pricing strategy remain uncertain.
How this was made

The 30-second read
Why it matters
Earnings miss may trigger sell‑off, but cash position and licensing cash inflow provide a floor.
Market read
Primary micro‑cap earnings release with mixed news; downside bias but mitigated by cash and licensing cash.
What to watch
Potential earlier FDA decision on Anifilm could catalyze upside if approved ahead of schedule.
Background
Aquestive Therapeutics is a micro‑cap biotech focused on epinephrine auto‑injector Anifilm and related licensing deals.
Ticker impact
Q3 2026 earnings released with revenue down to $7.6M and net loss of $16.5M, plus updates on Anifilm NDA resubmission and licensing deal.
likely pressure as the market prices in the revenue decline and widened loss
The earnings numbers are worse than prior year and the guidance is limited; however, the $10M upfront licensing payment and cash balance mitigate the downside.
Market effects
Biotech sector may see broader scrutiny on late-stage allergy drug pipelines.
Limited to US biotech investors.
Minimal global impact.
Counterpoint
The licensing deal and cash runway could support a short-term bounce despite earnings miss.
Key entities
- CompanyAquestive Therapeutics Inc
Biotech firm reporting Q3 2026 results.
- CompanyEton Pharmaceuticals
Licensee of Libervant receiving $10M upfront.


